Aakaar Medical Technologies Limited Reports H1 FY27 Profit Turnaround

Aakaar Medical Technologies Limited reported revenue from operations of INR 43.72 Cr in H1 FY27, up 72.6% from INR 25.32 Cr a year earlier. The company also moved from operating and net losses to EBITDA of INR 5.43 Cr and profit after tax of INR 3.54 Cr, according to its Q2 FY27 investor presentation.

What did Aakaar Medical Technologies Limited report for H1 FY27?

Aakaar Medical Technologies Limited reported a marked improvement in revenue and profitability for the first half of FY27. Revenue from operations rose to INR 43.72 Cr in H1 FY27 from INR 25.32 Cr in H1 FY26. This represents year-on-year growth of 72.6%.

The company reported EBITDA of INR 5.43 Cr, compared with an EBITDA loss of INR 0.23 Cr in the corresponding previous period. Profit after tax stood at INR 3.54 Cr, against a loss of INR 0.78 Cr in H1 FY26. The figures indicate that higher revenue was accompanied by a return to operating and net profitability.

The presentation does not include an earnings-call transcript for the quarter. Therefore, the reported figures reflect the investor presentation and should not be treated as management guidance. It also does not provide a separate capex amount or capex plan for H1 FY27.

How did Aakaar Medical Technologies Limited improve its margins?

Aakaar Medical Technologies improved its EBITDA margin to 12.42% in H1 FY27 from negative 0.91% in H1 FY26. Its PAT margin similarly rose to 8.10% from negative 3.10% during the same comparison period. These changes correspond with the company’s move into positive EBITDA and PAT.

The presentation identifies sales from imported or third-party brands and Aakaar’s own brands as important parts of the business. Imported and third-party brand sales revenue was INR 28.7 Cr in H1 FY27. Own-brand sales revenue was INR 14.9 Cr for the same period.

For comparison with the prior full year, imported or third-party brand revenue was INR 44.5 Cr in FY26, while own-brand revenue was INR 22.4 Cr. The H1 FY27 values are not directly comparable with the FY26 full-year numbers because the reporting periods differ. Still, they show that both revenue streams remained active contributors to the company’s first-half sales.

What is Aakaar Medical Technologies Limited’s business model?

Aakaar Medical Technologies operates as a business-to-business distributor and supplier of medical aesthetic products and devices. Its customers include dermatologists, plastic surgeons and aesthetic physicians, who use devices in treatments or may resell products to end consumers.

The company sells domestically manufactured products under its own brands and imported medical aesthetic devices sourced from countries including Korea, Spain, Italy and Austria. Its product portfolio includes aesthetics products for hair care, skin care and injectables, as well as aesthetic devices and device consumables.

The company’s historical investor information describes products such as oral supplements, hair serums, peels, medical facials, serum masks and topical botulinum toxin. Its devices and consumables address skin-care and hair-care applications and include categories such as hair-removal lasers, HydraFacial platforms and picosecond lasers.

This mix of own brands, imported brands and in-licensing arrangements is relevant to the H1 FY27 sales breakdown. It also places the company within the personal-care segment, with operations serving professional aesthetic and clinical channels rather than a direct-to-consumer retail model.

What does the presentation show about funding and expansion plans?

Aakaar Medical Technologies’ presentation shows an increase in share capital and reserves over recent years. Share capital increased from INR 0.7 Cr in FY23 and FY24 to INR 10.4 Cr in FY25 and INR 14.2 Cr in FY26. Reserves and surplus rose from INR 9.9 Cr in FY23 to INR 40.3 Cr in FY26.

Long-term borrowings, which were nil in FY23 and FY24, stood at INR 4.8 Cr in FY26. For H1 FY27, the presentation shows short-term borrowings of INR 18.89 Cr and long-term provisions of INR 1.15 Cr. Long-term provisions are distinct from borrowings and should not be read as additional debt.

The company has stated an aim of reaching more than 100 clinics for the Xelix platform in FY27 and more than 500 clinics from FY28 onward. The presentation does not specify the current number of Xelix clinics, the investment needed for this expansion, or a timetable within FY27.

The company had earlier raised up to INR 27 Cr through its IPO, with stated uses including working-capital requirements and general corporate expenses. Given the business-to-business distribution model, working capital and inventory funding are relevant operating considerations, although the presentation does not provide a separate H1 FY27 working-capital analysis.

Why do Aakaar Medical Technologies Limited’s H1 FY27 results matter?

Aakaar Medical Technologies’ H1 FY27 results matter because the company recorded substantial revenue growth while reversing losses at both EBITDA and PAT levels. Revenue increased by INR 18.40 Cr year-on-year, while EBITDA improved by INR 5.66 Cr and PAT improved by INR 4.32 Cr versus H1 FY26.

For investors, the reported margins provide a clearer measure of the first-half turnaround than revenue alone. EBITDA margin of 12.42% and PAT margin of 8.10% show positive profitability in the period, though the presentation does not provide management commentary on the factors behind the margin change or forecasts for the remainder of FY27.

The company is listed on NSE SME under the symbol AAKAAR. Its supplied fundamentals show a market capitalisation of INR 90 Cr, a price-to-earnings ratio of 14.40, return on equity of 12.17% and return on capital employed of 19.79%. These market data points are separate from the H1 FY27 investor-presentation results.

Conclusion

Aakaar Medical Technologies reported H1 FY27 revenue from operations of INR 43.72 Cr and returned to profitability, recording EBITDA of INR 5.43 Cr and PAT of INR 3.54 Cr. The first-half performance reflects growth in both imported or third-party brands and own-brand sales, alongside significantly improved EBITDA and PAT margins.

The next disclosed operating milestone is the company’s FY27 aim of expanding the Xelix platform to more than 100 clinics, followed by more than 500 clinics from FY28 onward. Investors will also need to monitor future disclosures for updates on clinic additions, borrowing levels, working-capital requirements and any capex details not included in the Q2 FY27 presentation.